Serum & Biocon Biologics agree to restructure equity investment
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Apollo continues to invest in genomics technology and research for better patient care
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
Subscribe To Our Newsletter & Stay Updated